lactic acid has been researched along with Lipodystrophy in 14 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Lipodystrophy: A collection of heterogenous conditions resulting from defective LIPID METABOLISM and characterized by ADIPOSE TISSUE atrophy. Often there is redistribution of body fat resulting in peripheral fat wasting and central adiposity. They include generalized, localized, congenital, and acquired lipodystrophy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Poly-L-lactic acid (PLLA) is an injectable filler used for the treatment of facial fat loss secondary to HIV and aging." | 9.12 | Safety and efficacy of poly-L-lactic acid in HIV lipoatrophy and lipoatrophy of aging. ( Hanke, CW; Redbord, KP, 2007) |
| " Forty patients were evaluated for adverse events (bruising, edema, erythema, subcutaneous papules) and satisfaction." | 5.36 | Modified poly-L-lactic acid injection technique: safety and efficacy of "cross-fanning" in non-HIV-related facial atrophy. ( Lee, JY; Schulman, MR; Skolnik, RA, 2010) |
| "Acne vulgaris affects up to 80% of people 11 to 30 years of age, and scarring can occur for up to 95% of these patients." | 5.35 | Injectable poly-L: -lactic acid: a novel sculpting agent for the treatment of dermal fat atrophy after severe acne. ( Sadove, R, 2009) |
| "Poly-L-lactic acid (PLLA) is an injectable filler used for the treatment of facial fat loss secondary to HIV and aging." | 5.12 | Safety and efficacy of poly-L-lactic acid in HIV lipoatrophy and lipoatrophy of aging. ( Hanke, CW; Redbord, KP, 2007) |
| " Suspected antiretroviral toxicities meeting these criteria include: HIV-associated lipodystrophy which can include peripheral lipoatrophy, lipohypertrophy and metabolic abnormalities; hyperlactatemia and lactic acidosis; and metabolic bone abnormalities such as decreased bone mineral density, osteoporosis and osteonecrosis." | 4.82 | Emerging drug toxicities of highly active antiretroviral therapy for human immunodeficiency virus (HIV) infection. ( Bondy, G; Heath, KV; Hogg, RS; Montaner, JS; O'Shaughnessy, MV; Singer, J, 2003) |
| " It frequently causes peripheral neuropathy and lipodystrophy and increases the risk of lactic acidosis and other high lactate syndromes." | 3.79 | Longitudinal lactate levels from routine point-of-care monitoring in adult Malawian antiretroviral therapy patients: associations with stavudine toxicities. ( Chagoma, N; Heyderman, RS; Kampira, E; Kaunda, S; Mallewa, J; Mukaka, M; Njalale, Y; van Oosterhout, JJ, 2013) |
| " Forty patients were evaluated for adverse events (bruising, edema, erythema, subcutaneous papules) and satisfaction." | 1.36 | Modified poly-L-lactic acid injection technique: safety and efficacy of "cross-fanning" in non-HIV-related facial atrophy. ( Lee, JY; Schulman, MR; Skolnik, RA, 2010) |
| "Acne vulgaris affects up to 80% of people 11 to 30 years of age, and scarring can occur for up to 95% of these patients." | 1.35 | Injectable poly-L: -lactic acid: a novel sculpting agent for the treatment of dermal fat atrophy after severe acne. ( Sadove, R, 2009) |
| "Osteopenia has been associated with antiretroviral therapy, particularly with protease inhibitors." | 1.31 | Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. ( Carr, A; Cooper, DA; Eisman, JA; Miller, J, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (85.71) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chagoma, N | 1 |
| Mallewa, J | 1 |
| Kaunda, S | 1 |
| Njalale, Y | 1 |
| Kampira, E | 1 |
| Mukaka, M | 1 |
| Heyderman, RS | 1 |
| van Oosterhout, JJ | 1 |
| Sadove, R | 1 |
| Levy, RM | 1 |
| Redbord, KP | 2 |
| Hanke, CW | 2 |
| Roca, B | 1 |
| Lee, JY | 1 |
| Schulman, MR | 1 |
| Skolnik, RA | 1 |
| Huff, B | 1 |
| Heath, KV | 1 |
| Montaner, JS | 1 |
| Bondy, G | 1 |
| Singer, J | 1 |
| O'Shaughnessy, MV | 1 |
| Hogg, RS | 1 |
| Humble, G | 1 |
| Mest, D | 1 |
| Vleggaar, D | 1 |
| Chow, DC | 1 |
| Day, LJ | 1 |
| Souza, SA | 1 |
| Shikuma, CM | 1 |
| Rendon, MI | 1 |
| Keeling, J | 1 |
| Carr, A | 1 |
| Miller, J | 1 |
| Eisman, JA | 1 |
| Cooper, DA | 1 |
2 reviews available for lactic acid and Lipodystrophy
| Article | Year |
|---|---|
Adverse drug reactions to antiretroviral medication.
Topics: Anti-HIV Agents; Bone Diseases, Metabolic; Bone Marrow; Cardiovascular System; Drug Hypersensitivity | 2009 |
Emerging drug toxicities of highly active antiretroviral therapy for human immunodeficiency virus (HIV) infection.
Topics: Acidosis, Lactic; Antiretroviral Therapy, Highly Active; Bone Diseases, Metabolic; DNA, Mitochondria | 2003 |
2 trials available for lactic acid and Lipodystrophy
| Article | Year |
|---|---|
Treatment of HIV lipoatrophy and lipoatrophy of aging with poly-L-lactic acid: a prospective 3-year follow-up study.
Topics: Aged; Aging; Cellulose; Cohort Studies; Female; Follow-Up Studies; HIV-Associated Lipodystrophy Synd | 2008 |
Safety and efficacy of poly-L-lactic acid in HIV lipoatrophy and lipoatrophy of aging.
Topics: Adult; Aged; Aged, 80 and over; Aging; Case-Control Studies; Drug-Related Side Effects and Adverse R | 2007 |
10 other studies available for lactic acid and Lipodystrophy
| Article | Year |
|---|---|
Longitudinal lactate levels from routine point-of-care monitoring in adult Malawian antiretroviral therapy patients: associations with stavudine toxicities.
Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Dru | 2013 |
Injectable poly-L: -lactic acid: a novel sculpting agent for the treatment of dermal fat atrophy after severe acne.
Topics: Acne Vulgaris; Chronic Disease; Cicatrix; Esthetics; Female; Humans; Injections, Intradermal; Lactic | 2009 |
Modified poly-L-lactic acid injection technique: safety and efficacy of "cross-fanning" in non-HIV-related facial atrophy.
Topics: Atrophy; Biocompatible Materials; Cosmetic Techniques; Face; Health Surveys; HIV Infections; Humans; | 2010 |
The case against Zerit.
Topics: HIV Infections; Humans; Insulin Resistance; Lactic Acid; Lipodystrophy; Mitochondria; Reverse Transc | 2002 |
FDA approves treatment for facial fat loss.
Topics: Adult; Face; Female; HIV Infections; Humans; Lactic Acid; Lipodystrophy; Male; Middle Aged; Polyeste | 2004 |
Soft tissue augmentation using sculptra.
Topics: Biocompatible Materials; Collagen; Humans; Lactic Acid; Lipodystrophy; Microspheres; Polyesters; Pol | 2004 |
Poly-L-lactic acid: consultation on the injection techniques.
Topics: Adult; Female; Humans; Injections, Subcutaneous; Lactic Acid; Lipodystrophy; Male; Middle Aged; Poly | 2006 |
Metabolic complications of HIV therapy.
Topics: Acidosis, Lactic; Anti-HIV Agents; Bone Diseases; Dyslipidemias; HIV Infections; Humans; Insulin Res | 2006 |
Poly-L-lactic acid for the treatment of trauma-induced facial lipoatrophy and asymmetry.
Topics: Accidents, Traffic; Cosmetic Techniques; Facial Injuries; Female; Humans; Lactic Acid; Lipodystrophy | 2008 |
Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy.
Topics: Absorptiometry, Photon; Acidosis, Lactic; Adult; Anti-HIV Agents; Body Composition; Body Weight; Bon | 2001 |